N
N-Gene
Focuses on the pharmacological exploitation of the natural defense mechanism of our cells
About N-Gene
N Gene is a biotechnology company focused on developing pharmacological solutions that exploit the natural defense mechanisms of cells. The company's lead compound, BGP 15, targets cellular stress responses, including heat shock protein and mitochondrial stress responses. This approach has shown therapeutic effects in a variety of serious diseases that currently lack efficient treatments. N Gene operates in the biotechnology and pharmaceutical markets, serving medical professionals, researchers, and healthcare providers. The business model revolves around the development and commercialization of innovative drugs, generating revenue through licensing agreements, partnerships, and direct sales. By addressing mitochondrial stress and promoting protein homeostasis, N Gene aims to improve patient outcomes in conditions characterized by cellular stress.
Source: Dealroom company dataAt a glance
- Founded
- 1997
- Headquarters
- New York City, United States
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Origin Investments
Soros Fund Management
Hiventures
Series B and later1 investor entered at this stage
- BABankár
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about N-Gene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See N-Gene on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.